Ubiquitin-specific peptidase 6 (USP6) (USP6)

Ubiquitin-specific peptidase 6 (USP6), also known as Tre-2 or TRE17, is a hominoid-specific deubiquitinating enzyme that regulates cellular processes by removing ubiquitin chains from substrate proteins, thereby preventing their proteasomal degradation (UniProt P35125). It plays a critical role in vesicular trafficking, actin cytoskeleton organization, and the activation of the NF-kappaB signaling pathway (Ye et al., 2010, PubMed: 20133633). In pathology, USP6 is primarily recognized as an oncogene in mesenchymal tumors such as Aneurysmal Bone Cyst (ABC) and Nodular Fasciitis. These diseases are characterized by chromosomal translocations that result in "promoter swapping," where the USP6 coding sequence is placed under the control of highly active promoters like CDH11, leading to massive mRNA-driven overexpression (Oliveira et al., 2004, PubMed: 14991000). The therapeutic strategy of targeting USP6 indirectly via mRNA-driven overexpression focuses on reducing the high levels of USP6 transcript using modalities such as RNA interference (RNAi) or antisense oligonucleotides (ASOs). By degrading the overexpressed mRNA, these treatments aim to lower USP6 protein levels and halt the oncogenic signaling cascades that drive tumor proliferation and bone resorption (Erickson-Johnson et al., 2011, PubMed: 21441912). While direct small-molecule inhibitors of the USP6 catalytic domain are in early-stage research, targeting the mRNA provides a specific mechanism to counteract the genetic driver of translocation-positive tumors. This approach is particularly valuable for treating locally aggressive or unresectable lesions where surgical options are limited.

Other names

Tre-2TRE17USP6 deubiquitinating enzymeHRP-1Proto-oncogene Tre-2

Inhibition of USP6 protein expression by targeting and degrading USP6 mRNA transcripts, thereby preventing the stabilization of oncogenic substrates.